Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration

Sagar Lonial, MD, provides an overview of the currently available treatment options in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss cytokine release syndrome (CRS) and the strategy to manage CRS in their clinic.

An overview of teclistamab in RRMM and the study methodology of using prophylactic tocilizumab to mitigate CRS associated with teclistamab

Study results show that prophylactic tocilizumab reduces CRS incidence and severity in patients receiving teclistamab.

Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.